NK-104: a novel synthetic HMG-CoA reductase inhibitor

Bibliography

• ENDO A: The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res. (1992) 33:1569–1582.
   PubMed Web of Science ®Google Scholar
• KNOPP RH: Drug treatment of lipid disorders. N Engl. J. Med. (1999) 341:498–511.
   PubMed Web of Science ®Google Scholar
• AOKI T, NISHIMURA H, NAKAGAWA S et al: Pharma-cological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneim-Forsch/Drug Res. (1997) 47:904–909.
   PubMed Web of Science ®Google Scholar
• YANAGITA T, HARA E, YOTSUMOTO H eta].: NK-104, a potent new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, enhances post-translational catabolism of apolipoprotein B-100 and inhibits secretion of apolipoprotein B-100 and triacylglycerols from HepG2 cells. Curr. Ther. Res. (1999) 60:423–434.
   Google Scholar
• OOYEN C, ZECCA A, BERSINO AM, CATAPANO AL: NK-1 04, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, decreases apolipo-protein B-100 secretion from Hep G2 cells. Atheroscle-rosis (1999) 145:87–95.
   Google Scholar
• YAMAMOTO K, TODAKA N, GOTO H et al: Effect ofNK-1 04, a new synthetic HMG-CoA reductase inhibitor, on triglyceride secretion and fatty acid oxidation in rat liver. Life Sci. (1999) 65:1493–1502.
   PubMed Web of Science ®Google Scholar
• SUZUKI H, AOKI T, TAMAKI T, SATO F, KITAHARA M,SAITO Y: Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea-pigs. Athero-sclerosis (1999) 146:259–270.
   PubMed Web of Science ®Google Scholar
• SUZUKI H, YAMAZAKI H, AOKI T et al.: Hypolipidemiceffect of NK-1 04 and other statins in guinea-pigs. Atherosclerosis (2000) 151:51. Abstract.
   Google Scholar
• AOKI T, YOSHINAKA Y, SUZUKI H et al: Effect of NK-104on postprandial triglyceride levels and lymph chylomicr on in rats. Atherosclerosis (2000) 151:50 (Abstract).
   Google Scholar
• KIMATA H, FUJINO H, KOIDE T, YAMADA Y, TSUNENARI Y, YANAGAWA Y: Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (1): absorption, distribution, metabolism and excretion in rats. Xeno. Metab. Disp. (1998) 13:484–498.
   Google Scholar
• FUJINO H, KOJIMA J, YAMADA Y, KANDA H, KIMATA H: Studies on the metabolic fate of NK-1 04, a new inhibitor of HMG-CoA reductase (4): interspecies variation in laboratory animals and humans. Xeno. Metab. Disp. (1999) 14:79–91.
   Google Scholar
• FUJINO H, YAMADA I, KOJIMA J, HIRANO M, MATSUMOTO H, YONEDA M: Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase(5): in vitrometabolism and plasma protein binding in animals and human. Xeno. Metab. Disp. (1999) 1 4:415–424.
   Google Scholar
• FUJINO H, YAMADA I, SHIMADA S, MATSUMOTO H, YONEDA M: Studies on the metabolic fate of itavastatin, a new inhibitor of FINIG-CoAreductase: in vivometabo-lism. Atherosclerosis (2000) 151:50. Abstract. of considerable interest
   Google Scholar
• NAKAYA N, KOJIMA J, KIMATA H, KUWAHATA R, NARUSHIMA H: NK-104: efficacy and tolerance of anew synthetic HMG-CoA reductase inhibitor in hypercho-lesterolemic volunteers. XII International Symposium on Drugs Affecting Lipid Metabolism (1995) Abstract 137.
   Google Scholar
• YAMADA N, GOTO Y, SAITO Y: NK-104 Clinical Evalua-tion Committee. Clinical effect of NK-104 (nisvastatin) on hyperlipidemia: Double-blind comparative dose-findings study in three parallel groups. XIII International Symposium on Drugs Affecting Lipid Metabo-lism (1998) Abstract 129.
   Google Scholar
• SAITO Y, GOTO Y, JAPAN ITAVASTATIN CLINICAL STUDY GROUP: Efficacy and safety of NK-104 (itavastain) in hyperlipidemic subjects: a double-blind comparative study. Atherosclerosis (2000) 151:154. Abstract.
   Google Scholar
• KAJINAMI K, KOIZUMI J, UEDA K et al.: Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Am. J. Cardiol. (2000) 85:178–183.
   PubMed Web of Science ®Google Scholar
• SASAKI J, IKEDA Y, YAMAMOTO K, AGETA M, ARAKAWAK: Efficacy and safety of a new HMG-CoA reductase inhibitor, NK-104, in patients with hypertriglyc-eridemia; randomized double-blind, cross-over placebo-controlled study. Atherosclerosis (2000) 151:73. Abstract.
   Google Scholar
• YAMADA N, SAITO Y, AKANUMA Y: Effect of itavastatinon lipid metabolism in NIDDM patients with hyperlipidemia. Atherosclerosis (2000) 151 :48-49. Abstract.
   Google Scholar
• TERAMOTO T, SAITO Y, NAKAYA N, THE JAPAN ITAVAS- TATIN CLINICAL STUDY GROUP: Clinical evaluation of NK-104 (itavastatin) in long-term treatment of patients with hyperlipidemia. Atherosclerosis (2000) 151 :53. Abstract.
   Google Scholar
• MABUCHI H, THE HOKURIKU FH STUDY GROUP: Long-term effects of NK-104 (itavastatin), a new HMG-CoA reductase inhibitor, in patients with heterozygous familial hypercholesterolemia. Athero-sclerosis (2000) 151:53. Abstract.
   Google Scholar
• JAPAN PHARMACEUTICAL INFORMATION CENTER: Drugs In Japan. (2000).
   Google Scholar
• LENNERNAS H, FAGER G: Pharmacodynamics and pharmacokinetics of HMG-CoA reductase inhibitors. Clin. Pharmacokinet. (1997) 32:403–425.
   PubMed Web of Science ®Google Scholar
• KITAHARA M, KANAKI T, TAMAKI T, TANAKA S, SAITO Y: NK-104 (nisvastatin) suppresses foam cell formation induced by denatured low density lipoprotein in J774 macrophages. XIII International Symposium on Drugs Affecting Lipid Metabolism (1998) Abstract 49.
   Google Scholar
• KITAHARA M, KANAKI T, TAMAKI T, SAITO Y: Itavastatin inhibits modified LDL-induced foam cell formation and scavenger pathway, mediated with Rab, Rho and Rac small G-protein, in RAW264.7 macrophages. Atherosclerosis (2000) 151:295. Abstract.
   Google Scholar
• SUZUKI H, YAMAZAKI H, AOKI T et al.: lipid-lowering and anti-atherosclerotic effect of NK-104 (nisvastatin), a new synthetic HMG-CoA reductase inhibitor, in WHHL rabbits. XIII International Symposium on Drugs Affecting Lipid Metabolism (1998) Abstract 53.
   Google Scholar
• KITAHARA M, KANAKI T, TOYODA K et al.: NK-104, a newly developed HMG-CoA reductase inhibitor, suppressed neointimal thickening by inhibiting smooth muscle cell growth and fibronectin produc-tion in balloon-injured rabbit carotid artery. Jpn. Pharmacol. (1998) 77:117–128.
   PubMedGoogle Scholar